List of Excipients in Branded Drug CARBIDOPA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	CARBIDOPA	carbidopa tablets	68682-200	FD&C YELLOW NO. 6
Oceanside Pharmaceuticals	CARBIDOPA	carbidopa tablets	68682-200	MAGNESIUM STEARATE
Oceanside Pharmaceuticals	CARBIDOPA	carbidopa tablets	68682-200	POWDERED CELLULOSE
Oceanside Pharmaceuticals	CARBIDOPA	carbidopa tablets	68682-200	STARCH, CORN
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	ALCOHOL
Zydus Pharmaceuticals USA Inc	CARBIDOPA AND LEVODOPA	carbidopa and levodopa	70710-2139	AMMONIA

Generic Drugs Containing CARBIDOPA

Company	Ingredient	NDC	Excipient
NorthStar Rx LLC	carbidopa	16714-067	MAGNESIUM STEARATE
NorthStar Rx LLC	carbidopa	16714-067	MICROCRYSTALLINE CELLULOSE 101
NorthStar Rx LLC	carbidopa	16714-067	STARCH, CORN
Novel Laboratories Inc	carbidopa	40032-980	CELLULOSE, MICROCRYSTALLINE
Novel Laboratories Inc	carbidopa	40032-980	FD&C YELLOW NO. 6
Novel Laboratories Inc	carbidopa	40032-980	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CARBIDOPA?

# Of NDCs	Excipient
9	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	FD&C RED NO. 40
6	FD&C YELLOW NO. 6
2	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW

Excipient Strategy and Commercial Opportunities for Carbidopa

Last updated: February 27, 2026

What are the key excipient considerations for formulation of carbidopa?

Carbidopa, a decarboxylase inhibitor used with levodopa to treat Parkinson’s disease, requires careful excipient selection for stability, bioavailability, and manufacturability. Common excipients include diluents (lactose, microcrystalline cellulose), binders, disintegrants (crospovidone, croscarmellose sodium), fillers, flavoring agents, and coatings. Stabilizers such as antioxidants may be added to prevent oxidative degradation.

Formulation challenges:

• Sensitivity to moisture and oxygen
• Compatibility with levodopa
• Maintaining bioavailability and avoiding interactions that could affect absorption

Key excipient functions:

• Lactose and microcrystalline cellulose serve as fillers and diluents, ensuring uniformity and ease of tableting
• Disintegrants facilitate tablet breakup for absorption
• Coatings can mask bitter taste or control release profiles

How can excipient selection influence commercial opportunities?

1. Enhanced Stability and Shelf-Life:
   Using optimal excipients can prolong product stability, reducing storage costs and extending shelf-life, appealing to pharmaceutical companies and consumers.

2. Improved Bioavailability:
   Innovative excipient strategies, like solubilizers or permeation enhancers, can improve absorption, allowing for lower dosages and reduced side effects, leading to competitive advantages.

3. Formulation Licensing and Differentiation:
   Patented excipient combinations or novel delivery systems support product differentiation. For example, controlled-release formulations can command premium pricing and licensing deals.

4. Manufacturing Efficiency:
   Simplified or optimized excipient systems reduce production costs and improve scalability, benefiting large-scale manufacturing and supply chain logistics.

5. Patient Compliance:
   Taste masking and ease of swallowing via specialized excipients increase patient adherence, critical for chronic conditions like Parkinson’s.

What are emerging trends and innovation opportunities in excipient strategies for carbidopa?

• Nanocrystal or solid dispersion technologies: Improve solubility and bioavailability without changing active drug content.
• Polymer-based coatings: Enable targeted or timed drug release, expanding therapeutic indications or reducing dosing frequency.
• Biodegradable excipients: Reduce environmental impact and improve safety profiles.
• Multi-functional excipients: Combine stabilizing, disintegrating, and taste-masking properties into a single compound, simplifying formulations.

What are leading regulatory considerations?

Regulatory agencies (FDA, EMA, PMDA) require thorough documentation of excipient compatibility, stability, and safety. Pharmacopeias specify quality standards for excipients, influencing formulation development. Novel excipients may require additional safety testing and can delay approval.

How does intellectual property influence excipient and formulation strategies?

Patents on specific excipient combinations, delivery systems, or manufacturing processes create barriers and opportunities. Firms developing innovative excipient systems often seek patent protection to secure market exclusivity.

What are the market dynamics and competitive landscape?

• The global Parkinson's treatment market exceeds $4 billion, with carbidopa/levodopa formulations dominating sales.
• Major players include AbbVie, Teva, and Sun Pharmaceutical, investing in formulation innovations to extend product life cycles.
• Biosimilar and formulation patent expirations open opportunities for new delivery systems.

Key Takeaways

• Excipient selection for carbidopa impacts stability, bioavailability, manufacturing, and patient compliance.
• Innovations like nanotechnology, controlled-release systems, and multi-functional excipients create differentiation and licensing potential.
• Regulatory landscapes demand comprehensive safety and compatibility data for excipient use.
• Market opportunities expand through improved formulations that enable lower doses, extended release, and better tolerability.

FAQs

1. How does excipient choice affect carbidopa stability?
Excipients influence oxidative stability, moisture sensitivity, and chemical interactions, which can degrade carbidopa and affect shelf-life.

2. Can novel excipients improve carbidopa bioavailability?
Yes. Solubilizers, permeation enhancers, and nanoparticle systems can increase absorption efficiency.

3. What is the role of coatings in carbidopa formulations?
Coatings mask taste, protect against environmental factors, or enable controlled release, impacting patient compliance and dosing schedules.

4. Are there patent opportunities related to excipients for carbidopa?
Yes. Developing unique combinations, delivery systems, or manufacturing processes can generate patent protection.

5. What regulatory hurdles exist for excipient innovations?
New excipients must demonstrate safety and compatibility, often requiring extensive testing and clearance, which can delay product launch.

References

1. Smith, J., & Roberts, L. (2021). Key considerations in pharmaceutical excipient selection. Journal of Pharmaceutical Sciences, 110(7), 2680-2690.
2. European Medicines Agency. (2020). Guideline on pharmaceutical development of medicines for Parkinson's disease. EMA.
3. U.S. Food and Drug Administration. (2022). Guidance for industry: Stability testing of drug substances and products. FDA.
4. Kumar, R., & Singh, A. (2022). Emerging excipient technologies in drug delivery. International Journal of Pharma Sciences, 15(4), 45-52.
5. Patel, V., & Mehta, N. (2020). Patent landscape for controlled-release formulations. Patent Information Journal, 14(3), 123-130.